Scalper1 News
Bristol-Myers Squibb (BMY) won approval for its oral hepatitis C virus (HCV) drug Daklinza in the European Union Wednesday, as the company continued to carve out a niche in the increasingly competitive HCV space. The EU approved Daklinza with sofosbuvir, also known as Gilead Sciences ‘ (GILD) Sovaldi, for all genotypes of the disease. This combo performed outstandingly in clinical trials, achieving a 100% cure rate in some groups. But Gilead Scalper1 News
Scalper1 News